Skip to Content
Home > About Us > Research and Grants Administration > Detail
<< Back to Results
The main purpose of this study is to compare any good and bad effects of using ABT-888 (Veliparib) (a “PARP” inhibitor) along with cisplatin to using cisplatin alone. This study is for patients that have metastatic triple negative breast cancer or have BRCA-mutation associated metastatic HER2 negative breast cancer.
View Additional Section Content
For more information about our research program and IRB, please contact: